Open Access

Maiwei Yangfei decoction prevents bleomycin‑induced pulmonary fibrosis in mice

  • Authors:
    • Yong Xu
    • Wenpan Peng
    • Di Han
    • Fanchao Feng
    • Zhichao Wang
    • Cheng Gu
    • Xianmei Zhou
    • Qi Wu
  • View Affiliations

  • Published online on: September 16, 2021     https://doi.org/10.3892/etm.2021.10741
  • Article Number: 1306
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Maiwei Yangfei (MWYF) is a compound Chinese herb that is safe and effective in the clinical setting in patients with pulmonary fibrosis (PF). The aim of the present study was to assess the role of a (MWYF) decoction in a bleomycin (BLM)‑induced PF mouse model and to investigate the underlying functional mechanism. Chemical components within the MWYF decoction were analysed using liquid chromatography‑mass spectrometry. A total of 50 C57BL/6 mice were randomly assigned to one of the following five groups with 10 mice per group: Control, model, low dose MWYF (20 g/kg), medium dose MWYF (40 g/kg) and high dose MWYF (60 g/kg). A mouse PF model was established by the tracheal instillation of BLM (5 mg/kg) prior to MWYF treatment, except for mice in the control group. After 21 days of treatment with MWYF, the mice were sacrificed and the body weights were recorded. In addition, pulmonary tissues and bronchial alveolar lavage fluid were collected. TNF‑α, IL‑6, IL‑17, hydroxyproline, pyridinoline and collagen I levels were determined using ELISA. Vimentin, α‑smooth muscle actin (α‑SMA), fibronectin, TGF‑β1, Smad3, TNF‑α, IL‑6, IL‑17, collagen I and collagen III were determined using western blotting. Vimentin and α‑SMA levels were also determined using immunofluorescence analysis. Collagens I and III were detected using immunohistochemical analysis and TGF‑β1 and Smad3 levels were determined using reverse transcription‑quantitative PCR. Following treatment with MWYF decoction, the body weight of the mice in the PF group increased, the degree of pulmonary alveolitis and PF was reduced, collagen levels were reduced and the expression levels of α‑SMA, vimentin and fibronectin were decreased. Although both protein and mRNA expression levels of TGF‑β1 and Smad3 were reduced, they remained higher than those observed in the control group. To conclude, MWYF decoction delayed the development of BLM‑induced PF in mice, where the functional mechanism was likely associated with the TGF‑β1/Smad3 signalling pathway.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu Y, Peng W, Han D, Feng F, Wang Z, Gu C, Zhou X and Wu Q: Maiwei Yangfei decoction prevents bleomycin‑induced pulmonary fibrosis in mice. Exp Ther Med 22: 1306, 2021
APA
Xu, Y., Peng, W., Han, D., Feng, F., Wang, Z., Gu, C. ... Wu, Q. (2021). Maiwei Yangfei decoction prevents bleomycin‑induced pulmonary fibrosis in mice. Experimental and Therapeutic Medicine, 22, 1306. https://doi.org/10.3892/etm.2021.10741
MLA
Xu, Y., Peng, W., Han, D., Feng, F., Wang, Z., Gu, C., Zhou, X., Wu, Q."Maiwei Yangfei decoction prevents bleomycin‑induced pulmonary fibrosis in mice". Experimental and Therapeutic Medicine 22.5 (2021): 1306.
Chicago
Xu, Y., Peng, W., Han, D., Feng, F., Wang, Z., Gu, C., Zhou, X., Wu, Q."Maiwei Yangfei decoction prevents bleomycin‑induced pulmonary fibrosis in mice". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1306. https://doi.org/10.3892/etm.2021.10741